The 2-component therapy is designed to lower serum acid (sUA) levels in patients with uncontrolled gout, thereby reducing the potential for flares and joint deformity. Study participants were randomly assigned 1:1:1 to receive NASP low dose, high dose, or placebo administered as an intravenous infusion every 28 days for a total of up to 12 infusions. In DISSOLVE I, 56% of the NASP high dose group and 48% of the NASP low dose group achieved sUA control vs 4% of the placebo group (both P <.0001). Regarding safety, mild to moderate stomatitis occurred in 3.4% of the low dose group and 9.2% of the high dose group, compared with 0% of the placebo group. Additionally, a greater number of infusion reactions were reported with NASP vs placebo.